Overactive Bladder (OAB)

At a glance

• What it is: Overactive bladder (OAB) is a symptom syndrome of urinary urgency - usually with daytime frequency and night-time waking to pass urine (nocturia) - with or without urgency urinary incontinence, in the absence of a urinary tract infection or other identifiable cause.^1,11,12
• How common it is: Population studies (including the EPIC and EpiLUTS multinational surveys) report OAB symptoms in roughly 12 to 17% of community-dwelling adults, rising with age and affecting both men and women.^2,3
• How it is investigated: A symptom-focused history, examination, urine dip and culture, a 3-day bladder diary, post-void residual measurement and a uroflow are usually enough to confirm OAB and rule out the most common look-alikes. Cystoscopy and urodynamic studies are reserved for selected cases.^11,12,13
• How it is treated: A stepped pathway. Step 1 is behavioural therapy (timed voiding, fluid and bladder-irritant adjustment, weight loss, pelvic-floor muscle training, bladder retraining). Step 2 is oral medication: an anticholinergic (for example oxybutynin, solifenacin, tolterodine) or the beta-3 agonist mirabegron, alone or in combination. Step 3 is advanced therapy: intradetrusor onabotulinumtoxinA (Botox) injections, percutaneous tibial nerve stimulation (PTNS), or sacral neuromodulation. Each step is reviewed at a defined interval before stepping up.^11,12,13
• What good treatment looks like: A measurable reduction in urgency, frequency and incontinence episodes (recorded on the bladder diary), an acceptable side-effect profile, and a treatment that the patient is willing to continue. Where treatment is not working, the next step on the pathway is offered rather than persisting with a step that has failed.^11,12
• Where Urology NSW sits: Dr Raji Kooner manages the full OAB pathway, including the advanced therapies (Botox bladder injections and sacral neuromodulation), and works with continence physiotherapists for the behavioural and pelvic-floor steps.

What is overactive bladder?

OAB is defined by the International Continence Society (ICS) as a symptom syndrome of urinary urgency, usually accompanied by daytime frequency and nocturia, with or without urgency urinary incontinence, and in the absence of urinary tract infection or other identifiable pathology.^1,11 Urgency - the sudden compelling desire to pass urine that is difficult to defer - is the central symptom; frequency, nocturia and leakage are the consequences.^1,11

OAB is divided into OAB-dry (urgency and frequency without leakage) and OAB-wet (urgency with leakage of urine before reaching the toilet). The two are different ends of the same condition; the treatment pathway is the same.¹¹

OAB is not stress urinary incontinence (leakage on coughing, sneezing or exercise from a weakened sphincter), and the two are managed differently. Some people have features of both - mixed urinary incontinence - in which case the most bothersome component is treated first.^11,12 Stress incontinence after prostate surgery is covered separately on the urinary incontinence after prostatectomy page.

How common is it?

Large epidemiological surveys have repeatedly placed the prevalence of OAB symptoms in the community in the 12 to 17% range:

• The EPIC study (Irwin et al. 2006) - a population-based cross-sectional study of 19,165 adults across five countries - reported OAB symptoms in 11.8% of men and 12.8% of women aged 18 and over.²
• The EpiLUTS study (Coyne et al. 2009) - a 30,000-respondent survey across the United States, United Kingdom and Sweden - reported OAB-type symptoms (urgency at least sometimes) in 17 to 18% of adults, with women slightly more often affected than men.³
• OAB prevalence rises with age in both men and women. Nocturia in particular becomes much more common from the sixth decade onwards.^2,3,11

OAB is therefore one of the most common conditions seen in urology and general practice. It is also one of the most under-reported - many people accept urgency, frequency and nocturia as a normal part of getting older, when they are in fact treatable.^11,12

How is OAB investigated?

The first consultation is largely about confirming OAB, ruling out the conditions that look like OAB but are managed differently, and quantifying the symptom load so that the response to treatment can be measured later.

History and examination

A focused history asks about the pattern, severity and impact of urgency, frequency, nocturia and any leakage; about fluid intake (volume, type, timing - especially caffeine and alcohol); about bowel habit (chronic constipation worsens OAB and is often missed); about any neurological symptoms; and about previous pelvic surgery, radiation, prolapse or incontinence procedures.^11,12

Examination includes an abdominal examination, a focused pelvic / prostate examination as appropriate, and a screening neurological examination of the lower limbs and perineum.^11,12

Bladder diary (frequency-volume chart)

A 3-day bladder diary is the single most useful investigation in OAB. The patient records, for three consecutive 24-hour periods, the time and volume of every drink, the time and volume of every void, every urgency episode and every leakage. The diary objectively documents the daytime and night-time voiding pattern, total fluid intake, functional bladder capacity, and the dominant pattern (true urgency versus polyuria versus nocturnal polyuria).^11,12,13

A printable input/output chart suitable for this purpose is in the downloadable resources below.¹⁴

Urine and basic tests

A urine dipstick and, where indicated, a urine culture exclude infection and screen for haematuria. Renal function bloods are checked when relevant. Post-void residual urine is measured (usually by bedside ultrasound) to exclude incomplete bladder emptying as a contributor to frequency or urgency.^11,12

Uroflow and post-void residual

A non-invasive uroflow (the patient passes urine into a flow meter when their bladder feels comfortably full) and a post-void residual ultrasound together exclude bladder outlet obstruction and incomplete emptying. In men with OAB, an obstructing prostate is the most common reversible contributor and may need to be addressed in parallel with OAB treatment.^11,12

Cystoscopy and urodynamics (selected cases)

Cystoscopy and urodynamic studies are not needed in every patient with OAB. They are reserved for situations in which the diagnosis is in doubt, the symptoms are not responding to first- and second-line treatment, there is haematuria, there is suspected obstruction, there is suspected neurogenic bladder, or surgical intervention (Botox, sacral neuromodulation, augmentation) is being considered.^11,12,13

Urodynamic testing is covered separately on the urodynamics page.

The stepped care pathway

International guidelines (EAU, AUA / SUFU, NICE, USANZ) all describe OAB management as a stepped pathway: simple measures first, then oral medication, then advanced therapy, with a defined review point at each step. Steps are added or escalated only after a step has had time to work.^11,12,13,15

Step 1 - Behavioural therapy and pelvic-floor strategies (4 to 6 weeks)

First-line management for almost every patient with OAB is non-pharmacological. The first review is typically at 4 to 6 weeks. The components are:

• Fluid management. Total fluid intake of approximately 1.5 to 2.0 litres per day in most adults, weighted to earlier in the day. Avoiding the under-drinking that produces concentrated, irritant urine is as important as avoiding the over-drinking that produces large diary volumes.^11,12
• Bladder irritants. Caffeine and alcohol are the two best-studied bladder irritants. A trial reduction (or removal) of coffee, tea, cola and energy drinks for 4 weeks is reasonable and often produces a measurable diary improvement.^11,12
• Timed voiding and bladder retraining. Voiding to a clock at gradually lengthening intervals (for example every 60 minutes initially, lengthening by 15 minutes per week as tolerated) re-trains the bladder to hold larger volumes between voids. Suppression strategies (deep breathing, perineal squeeze, distraction) are used when an urge arrives early.^11,12,16
• Pelvic-floor muscle training. A correctly performed pelvic-floor contraction transiently inhibits detrusor contraction and is the cornerstone of behavioural therapy for both OAB and mixed urinary incontinence. Best results are seen with supervised teaching by a continence physiotherapist rather than written instructions alone.^11,12,17
• Weight loss, where the body mass index is elevated. Weight loss is one of the few interventions with randomised evidence of benefit for both stress and urgency incontinence (Subak et al. 2009).¹⁷
• Bowel management. Constipation worsens urgency and frequency by mechanical and reflex mechanisms, and a bowel-management plan (fibre, fluid, regular toileting, where needed laxatives) is part of the standard OAB plan.^11,12
• Medication review. Diuretics taken late in the day, drugs with anticholinergic load, and medications that increase urine production should be reviewed and rescheduled where possible.^11,12

Behavioural therapy alone produces a clinically meaningful reduction in urgency and incontinence episodes in a substantial proportion of patients and is recommended as first-line in EAU, AUA / SUFU and NICE guidelines.^11,12,13 A printable bladder-training leaflet and pelvic-floor exercise guides for men and for women are in the downloadable resources below.^17,18,19

Step 2 - Oral medication (8 weeks)

If urgency, frequency or incontinence remain bothersome after a fair trial of behavioural therapy, an oral medication is added. Two pharmacological classes are first-line:

Antimuscarinic / anticholinergic agents

Antimuscarinic agents (sometimes called anticholinergics) block muscarinic receptors on the detrusor smooth muscle of the bladder wall and reduce involuntary contractions. The Australian-PBS-listed agents most commonly used in OAB include oxybutynin (immediate or extended release), solifenacin (Vesicare), tolterodine and darifenacin. Choice between them is largely driven by side-effect profile and tolerability rather than efficacy - randomised comparisons show broadly similar reductions in urgency, frequency and incontinence episodes between agents.^4,11,12,20

Common side effects include dry mouth, constipation, dry eyes, blurred vision, indigestion and (less commonly) urinary retention. Less obvious but important is the cognitive side-effect profile: anticholinergics cross the blood-brain barrier (more so for oxybutynin than for solifenacin or trospium) and have been linked in observational data to worsened cognition in older adults. Long-running cohort data (Gray et al. 2015, Coupland et al. 2019) reported an association between cumulative anticholinergic exposure and dementia risk in older populations - an association rather than proof of cause, but enough that current guidelines recommend caution and the lowest effective dose, particularly over the age of 65 and in patients with cognitive impairment.^5,6,11,12

Antimuscarinics are contraindicated or used with caution in narrow-angle glaucoma, severe constipation or gastric retention, urinary retention or significantly elevated post-void residual, and where there is a concern about cognitive side effects. Concomitant cholinesterase inhibitors (used for dementia) and antimuscarinics work against each other and are usually avoided.^11,12

Beta-3 adrenergic agonist

Mirabegron (Betmiga) is a beta-3 adrenergic receptor agonist that relaxes the detrusor smooth muscle during the storage phase, increasing functional bladder capacity. It does not block muscarinic receptors and therefore does not produce the dry mouth, constipation and cognitive side-effects of the anticholinergics.^7,11,12,21

Pivotal randomised placebo-controlled trials (Khullar et al. 2013, Nitti et al. 2013) and a meta-analysis (Cui et al. 2014) showed reductions in incontinence episodes and micturition frequency at 12 weeks comparable to those of antimuscarinic agents, with a different side-effect profile. The most common side effects are hypertension (typically a small mean rise in blood pressure - blood pressure should be checked at 10 to 14 days), headache, urinary tract infection, nasopharyngitis and tachycardia or palpitations. Mirabegron is contraindicated in severe uncontrolled hypertension.^7,8,21

Combination therapy

For patients with persistent symptoms on monotherapy, the BESIDE and SYNERGY randomised trials (Drake et al. 2016; MacDiarmid et al. 2016) showed that adding mirabegron to solifenacin (or vice versa) is more effective than either agent alone, with an acceptable side-effect profile - the two drug classes target different receptors and combine well.^9,10,12

The standard review point at Step 2 is 8 weeks on a single agent, or 8 weeks on combination therapy. If symptoms remain bothersome at that point, the choice is to switch agents within Step 2 or to step up to advanced therapy (Step 3).^11,12,13

Step 3 - Advanced therapy

For OAB that has not responded to behavioural therapy and to an adequate trial of oral medication, three advanced-therapy options are recognised in EAU, AUA / SUFU and NICE guidelines:^11,12,13

• Intradetrusor onabotulinumtoxinA (Botox) bladder injections.
• Percutaneous tibial nerve stimulation (PTNS).
• Sacral neuromodulation (sacral nerve stimulation).

These three options are not in a fixed order; the right choice depends on patient anatomy, comorbidities, the willingness to perform clean intermittent self-catheterisation (relevant for Botox), proximity to a clinic that delivers PTNS sessions, and patient preference after a structured discussion of trade-offs.^11,12,13 Each is described in detail in the next section.

Advanced therapy in detail

Intradetrusor onabotulinumtoxinA (Botox) bladder injections

OnabotulinumtoxinA (Botox) injected directly into the bladder wall blocks the release of acetylcholine at the neuromuscular junction of the detrusor muscle, reducing involuntary detrusor contractions and increasing functional bladder capacity. The licensed dose for idiopathic OAB is 100 units, divided across approximately 20 injection sites, given via a flexible or rigid cystoscope under local or light general anaesthesia as a day procedure.^22,23

The pivotal randomised trials of Botox 100 U for idiopathic OAB (Nitti et al. 2013; Chapple et al. 2013) reported significant reductions in daily urgency-incontinence episodes versus placebo, improvements in quality-of-life scores, and a typical durability of around 6 to 9 months per cycle, with re-treatment as symptoms return.^22,23 The randomised ROSETTA trial (Amundsen et al. 2016) directly compared intradetrusor Botox 200 U with sacral neuromodulation in women with refractory urgency incontinence and reported a small but statistically significant advantage in incontinence-episode reduction for Botox at 6 months, balanced against a higher rate of urinary tract infection and need for self-catheterisation in the Botox arm.²⁴

Side effects and considerations: the most important specific risks of Botox bladder injections are urinary tract infection and incomplete bladder emptying requiring temporary clean intermittent self-catheterisation (CISC). Real-world series report CISC rates in the order of 5 to 10% with the 100 U dose, and approximately one in five patients with the 200 U dose used in some refractory cases. Patients are counselled about CISC before the procedure and ideally have a brief teaching session with a continence nurse.^22,23,24

A short oral antibiotic course is given according to hospital protocol around the procedure. Light haematuria for one to two days is common. Re-treatment is typically performed when symptoms return - usually 6 to 9 months later for the 100 U dose.^22,23

Percutaneous tibial nerve stimulation (PTNS)

PTNS delivers low-amplitude electrical stimulation through a fine needle electrode placed near the posterior tibial nerve at the ankle. The signal travels up the tibial nerve and into the sacral plexus (S2-S4), which shares innervation with the bladder, and modulates the reflex that drives urgency.^11,12,25

A standard PTNS course is 12 weekly 30-minute sessions, after which responders move on to a less frequent maintenance schedule (typically once every 2 to 4 weeks). The pivotal randomised SUmiT trial (Peters et al. 2010) reported that PTNS was significantly more effective than sham at 12 weeks in reducing urgency-incontinence episodes; the STEP trial (MacDiarmid et al. 2010) reported sustained benefit when responders continued maintenance therapy for up to 3 years.^25,26

PTNS is well tolerated. The most common adverse events are minor bleeding, bruising or discomfort at the needle site, and rarely a vasovagal episode. PTNS does not typically cause urinary retention and does not have systemic side effects, which makes it an option for patients who cannot or do not want to take oral medication and who do not want an implant.^25,26 The main practical consideration is the time and travel required for the weekly sessions; PTNS is currently delivered through specialist continence and urology centres rather than every general urology clinic.

Sacral neuromodulation (sacral nerve stimulation)

Sacral neuromodulation (SNM) - sometimes called sacral nerve stimulation - delivers continuous low-level electrical stimulation to one of the S3 sacral nerve roots through a thin lead implanted into the S3 foramen and connected to a small implanted pulse generator under the skin of the upper buttock. The mechanism is neuromodulation of the bladder-pelvic-floor reflex pathway rather than direct stimulation of the bladder wall.^11,12,27

Treatment is delivered in two stages:

1. Test phase / staged trial. A test lead is placed under image guidance into the S3 foramen and connected to an external stimulator. The patient keeps a bladder diary across a 1- to 4-week trial period. The test is judged a success if there is a clinically meaningful improvement (typically defined as at least a 50% reduction in urgency-incontinence or frequency episodes on the diary).^11,12,27
2. Implant phase. If the test phase is successful, the temporary lead is replaced with a permanent quadripolar lead in the same position and connected to a small implanted pulse generator under the skin of the upper buttock. The device is programmed in clinic over the following weeks.^11,12,27

Long-term published follow-up (typically the InterStim registry data and the randomised InSite study) shows durable benefit in approximately two-thirds of implanted patients at 5 years for urgency incontinence, and a comparable durability for non-obstructive urinary retention - which is the second main licensed indication. Sacral neuromodulation also has a published effect on faecal incontinence and constipation, and some patients with combined bladder and bowel dysfunction are referred to colorectal services to consider sacral neuromodulation for both indications in a single device.^27,28

Side effects and considerations: the main specific risks of sacral neuromodulation are pain at the implant site, lead migration, infection (low but not zero, as for any implant), the need for surgical revision over the lifetime of the device, and the practical implications of having an implanted electrical device (most modern devices are MR-conditional - patients should always inform the radiology department of the implant before any MRI). Battery life of the latest rechargeable devices is approximately 15 years; non-rechargeable devices typically need replacement every 4 to 7 years depending on settings.^27,28

Where each option sits

A short comparison of the three Step-3 options:

• Botox - day-procedure cystoscopic injection, no implant, durable for 6 to 9 months per cycle, requires willingness to perform clean intermittent self-catheterisation if voiding becomes incomplete. Re-treatment as a clinic procedure indefinitely.^22,23,24
• PTNS - office-based, no implant, no medication, requires 12 weekly visits up front and ongoing maintenance. Best for patients prepared to commit to the weekly schedule and who want to avoid any implant or surgical step.^25,26
• Sacral neuromodulation - 2-stage implant, the only option that can be tested first before committing to permanent implant, durable in approximately two-thirds of implanted patients at 5 years, also indicated for non-obstructive urinary retention and (separately) for faecal incontinence and constipation.^27,28

Position in current guidelines

• European Association of Urology (EAU) guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (2024 update). The OAB pathway is described as behavioural therapy first, then antimuscarinic or beta-3 agonist (alone or in combination), then advanced therapy (Botox, PTNS, sacral neuromodulation) for refractory symptoms.¹¹
• American Urological Association (AUA) / Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guideline on Diagnosis and Treatment of Idiopathic Overactive Bladder in Adults (2024 amendment). The same three-step pathway, with explicit recommendation for PTNS, intradetrusor onabotulinumtoxinA and sacral neuromodulation as third-line options.¹²
• National Institute for Health and Care Excellence (NICE). NICE guideline NG123 (Urinary incontinence and pelvic organ prolapse in women: management, 2019) describes the same stepped pathway and recommends supervised pelvic-floor muscle training and bladder training as first line, with antimuscarinics or mirabegron as second line, and Botox / PTNS / sacral neuromodulation for refractory cases, after specialist discussion of catheterisation and implant considerations.¹³
• Continence Foundation of Australia. Plain-English national consumer resource on bladder health, supervised pelvic-floor training, fluid and bowel management, and the steps of OAB care; aligned with the international guidelines above.¹⁵

Where the evidence is not yet definitive

• Long-term cognitive safety of antimuscarinic agents in older adults remains an area of active research; published cohort associations between cumulative anticholinergic burden and incident dementia are observational and cannot prove causation.^5,6
• Comparative effectiveness data between the Step-3 options (Botox, PTNS, sacral neuromodulation) come largely from observational series; the ROSETTA randomised trial of Botox 200 U vs sacral neuromodulation is one of the few head-to-head comparisons.²⁴
• The optimal Botox dose for idiopathic OAB in older adults with a higher baseline risk of incomplete bladder emptying (and therefore CISC) is an active area of research; lower doses (50 U) have been studied as a less retention-prone alternative in selected patients.^22,23
• Long-term durability data beyond 5 years for sacral neuromodulation are dominated by registry data rather than randomised follow-up.^27,28

Who is suitable?

Almost any adult with OAB symptoms is suitable for the first step of the pathway (behavioural therapy and pelvic-floor strategies). The decision points further along the pathway depend on:

• Severity and impact of symptoms on day-to-day life and sleep.^11,12
• Whether the patient has tried behavioural changes already and what those produced.^11,12
• Cardiovascular and cognitive comorbidity, current medications and the anticholinergic burden of those medications.^5,6,11,12
• In men, whether an obstructing prostate is contributing - in which case the BPH treatment pathway runs in parallel.^11,12
• Pelvic floor and pelvic organ prolapse status in women.^11,13
• Willingness to perform clean intermittent self-catheterisation (relevant for Botox) and willingness to consider an implanted device (relevant for sacral neuromodulation).^22,23,27
• Practical considerations - distance from a continence clinic that delivers PTNS or sacral neuromodulation, work and travel commitments around weekly PTNS sessions, MRI safety considerations for implanted devices.^25,26,27

OAB is also worth re-evaluating periodically. A treatment that worked well at one point may need to be stepped up or stepped down as the patient ages, as comorbidities accrue, and as new evidence emerges.^11,12

What to expect at the first appointment

A typical first OAB appointment takes 30 to 45 minutes. It usually includes:

• A focused history of urgency, frequency, nocturia and any leakage; fluid intake; bowel habit; previous treatments tried; current medications; and impact on day-to-day life.
• A focused examination (abdominal and, where relevant, pelvic / prostate examination, and a screening neurological examination).
• A urine dipstick and culture if not already done in the community.
• An ultrasound bladder scan to measure the post-void residual volume.
• A 3-day bladder diary to take home and complete.
• An initial behavioural plan (fluid, bladder irritants, timed voiding, pelvic-floor referral where appropriate).

The first review is usually arranged at 4 to 6 weeks, by which point the bladder diary is back, the behavioural plan has had time to act, and the decision about whether to add medication can be made. If symptoms are mild and the diary improvement is good, no medication may be needed.

Risks and considerations across the pathway

Every patient is counselled on the relevant risks at each step of the pathway. The most common ones are:

• Antimuscarinic side effects. Dry mouth, constipation, dry eyes, blurred vision, indigestion, less commonly urinary retention. Possible cognitive side effects in older adults; antimuscarinics with high central penetration (oxybutynin, in particular) are usually avoided in patients with cognitive impairment.^5,6,11,12
• Beta-3 agonist (mirabegron) side effects. Hypertension (blood pressure check at 10 to 14 days), headache, urinary tract infection, nasopharyngitis, palpitations or tachycardia. Contraindicated in severe uncontrolled hypertension.^7,8,21
• Botox bladder injection side effects. Urinary tract infection, light haematuria for a day or two after the procedure, and incomplete bladder emptying that may require temporary clean intermittent self-catheterisation. Re-treatment is typically required every 6 to 9 months in responders.^22,23
• PTNS side effects. Local needle-site discomfort, bruising or minor bleeding. The main practical consideration is the 12-weekly schedule and ongoing maintenance.^25,26
• Sacral neuromodulation side effects. Pain at the implant site, lead migration, infection (low but not zero, as for any implant), the need for surgical revision over the lifetime of the device, and MRI considerations (most modern devices are MR-conditional - inform the radiology department of the implant before any MRI scan).^27,28
• What is not on the OAB pathway. Routine cystoscopy and routine urodynamics are not done in everyone; bladder augmentation surgery and urinary diversion are reserved for very rare neurogenic or end-stage cases where every other option has failed.^11,12

OAB at Urology NSW

OAB is a common and very treatable condition, and most patients move through the stepped pathway successfully without ever needing advanced therapy. Where advanced therapy is required, Dr Raji Kooner offers cystoscopic Botox bladder injections and sacral neuromodulation as part of the standard practice, and works with continence physiotherapists for the behavioural and pelvic-floor steps. Urodynamic testing, where indicated, is arranged in parallel - see the urodynamics page.

Patients who would like to discuss OAB - whether starting at Step 1 or considering Step 3 after years of medication - are welcome to request a second opinion or to telephone the rooms to arrange a consultation. There is no fee for a discussion about which step on the pathway is appropriate; it is part of the standard consultation.

Frequently asked questions

Is OAB the same as a "weak bladder"?

Not exactly. OAB is about the bladder squeezing when it should not - producing urgency. A "weak bladder" in everyday language sometimes also means stress urinary incontinence (leakage on coughing, sneezing or exercise from a weakened sphincter). The two are different and are managed differently. Many patients have features of both - mixed urinary incontinence - in which case the most bothersome component is treated first.^11,12

Will I need a urodynamic test?

Not in every case. Most OAB is diagnosed and treated on the basis of history, bladder diary and basic tests. Urodynamics is reserved for situations in which the diagnosis is in doubt, the symptoms are not responding, there is suspected obstruction or neurogenic bladder, or surgical intervention is being considered.^11,12,13 See the urodynamics page for a full description.

How long should I try a new treatment before deciding it has not worked?

Behavioural therapy is reviewed at approximately 4 to 6 weeks. Oral medications (single agent or combination) are reviewed at approximately 8 weeks. Botox is reviewed at approximately 4 to 6 weeks (peak effect by 4 weeks, then plateau). Sacral neuromodulation is judged on the test phase before committing to the implant. PTNS is judged after the 12-week induction course.^{11,12,13,22,25,27}

I have heard anticholinergic OAB tablets are not safe in older adults. Is that right?

Cohort studies have reported an association between cumulative anticholinergic exposure over many years and an increased risk of incident dementia in older adults (Gray et al. 2015; Coupland et al. 2019). The evidence is observational and cannot prove the medication caused the dementia, but it has prompted current guidelines to recommend the lowest effective dose, preference for agents with low central penetration (such as solifenacin or trospium over oxybutynin) and a low threshold for switching to mirabegron in older adults.^5,6,11,12

Will I have to self-catheterise after Botox?

Possibly. With the licensed 100 U dose for idiopathic OAB, real-world series report clean intermittent self-catheterisation rates in the order of 5 to 10%; with the higher 200 U dose used in some refractory cases, approximately one in five patients catheterise temporarily. Patients are taught what to expect and (where appropriate) given a brief teaching session before the procedure so that, if it is needed, it is straightforward and short-term.^22,23,24

Is sacral neuromodulation reversible?

The test phase of sacral neuromodulation is fully reversible - the temporary lead is removed in clinic if the test does not work. The permanent implant can also be removed at a subsequent operation if needed. The main reasons for revision over the lifetime of a permanent device are battery replacement (for non-rechargeable devices, every 4 to 7 years), lead-related issues, and infection (uncommon).^27,28

Will I need any of this lifelong?

Some patients can step down therapy over time - particularly behavioural therapy and oral medication - if symptoms have settled. Advanced therapy (Botox, PTNS, sacral neuromodulation) is generally an ongoing commitment for as long as it is helping. The treatment plan is reviewed periodically; what worked at one stage of life may need to be stepped up or stepped down as the patient ages.^11,12

Is there anything I can do today?

Three things are worth starting before the first appointment: (1) fill in a 3-day bladder diary using the printable input/output chart in the resources section below; (2) try cutting caffeine and alcohol for 4 weeks; and (3) make sure constipation is being managed well. These three steps are the foundation of the rest of the pathway and are often surprisingly effective on their own.^11,12,14,16